Biocept Inc (NASDAQ:BIOC) gapped down before the market opened on Wednesday . The stock had previously closed at $1.44, but opened at $1.67. Biocept shares last traded at $3.23, with a volume of 328930 shares traded.
A number of equities research analysts have commented on BIOC shares. ValuEngine raised shares of Biocept from a “hold” rating to a “buy” rating in a report on Thursday, November 1st. Dawson James reaffirmed a “buy” rating on shares of Biocept in a research note on Wednesday, October 3rd. Finally, Zacks Investment Research raised shares of Biocept from a “sell” rating to a “hold” rating in a research note on Tuesday, November 20th.
The company has a market cap of $5.00 million, a PE ratio of -0.11 and a beta of 1.61. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.50 and a current ratio of 2.63.
An institutional investor recently bought a new position in Biocept stock. Dimensional Fund Advisors LP acquired a new position in shares of Biocept Inc (NASDAQ:BIOC) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 39,445 shares of the medical research company’s stock, valued at approximately $108,000. Dimensional Fund Advisors LP owned about 1.74% of Biocept at the end of the most recent reporting period. Institutional investors own 10.47% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Biocept (BIOC) Shares Gap Down to $1.67” was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://www.tickerreport.com/banking-finance/4081069/biocept-bioc-shares-gap-down-to-1-67.html.
Biocept Company Profile (NASDAQ:BIOC)
Biocept, Inc, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms.
Recommended Story: Does the discount rate affect the economy?
Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with MarketBeat.com's FREE daily email newsletter.